Medical device giant St. Jude Medical (NYSE:STJ) announced new clinical results for its migraine-management implants, reporting significant relief for patients who, on average, spend more days with migraines than without.
At 12 weeks of follow-up, St. Jude provided pain relief in 42% of the patients, with 53% ranking that relief as "excellent" or "good," according to a press release.
"For the millions who suffer from chronic migraine, these study results are important, as they confirm that peripheral nerve stimulation of the occipital nerve may help improve their quality of life and lessen the number of days per month they suffer with this debilitating condition," lead investigator and former American Headache Society president Dr. Stephen Silberstein said in prepared remarks.
St. Jude’s Genesis device is an implantable nerve stimulation system that delivers mild electrical pulses to the occipital nerves at the back of the head.
The study implanted 157 patients with Genesis devices, according to a press release. Those in the active group began receiving stimulation right away, while the control group’s stimulator remained off for the 12 weeks of the study.
That’s more good news for St. Jude’s neuromodulation business, which earlier this week won CE Mark approval in the European Union for the Eon Mini neurostimulator, which the company calls the smallest rechargeable device for treatment of chronic migraine.